Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amoxicillin trihydrate, quantity: 286.96 mg (equivalent: amoxicillin, qty 250 mg) - capsule, hard - excipient ingredients: titanium dioxide; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; sodium lauryl sulfate; gelatin; croscarmellose sodium; iron oxide yellow; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - it is indicated for the treatment of the following infections due to susceptible strains of sensitive organisms. note: therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. however, in emergency cases where the causative organism has not been identified, therapy with amoxycillin may be useful. clinical judgement will decide whether combination with another antibiotic would provide a sufficiently broad spectrum of activity pending sensitivity test results. skin and skin structure: staphylococcus, non-penicillinase producing; streptococcus; e. coli (see section 5.1 pharmacodynamic properties - microbiology). respiratory (acute and chronic): h. influenzae; streptococcus; strep. pneumoniae; staphylococcus, non-penicillinase producing; e. coli (see section 5.1 pharmacodynamic properties - microbiology). genitourinary tract (complicated and uncomplicated, acute and chronic): e.coli (see section 5.1 pharmacodynamic properties - microbiology), p. mirabilis and strep. faecalis. gonorrhoea: n.gonorrhoeae (non-penicillinase producing). prophylaxis of endocarditis: amoxycillin may be used for the prophylaxis of bacterial endocarditis in individuals at particular risk, such as those with a prosthetic heart valve or those who have previously had endocarditis.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amoxicillin trihydrate, quantity: 573.921 mg (equivalent: amoxicillin, qty 500 mg) - capsule, hard - excipient ingredients: magnesium stearate; titanium dioxide; colloidal anhydrous silica; sodium lauryl sulfate; gelatin; croscarmellose sodium; iron oxide black; microcrystalline cellulose; iron oxide red; iron oxide yellow; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; potassium hydroxide - it is indicated for the treatment of the following infections due to susceptible strains of sensitive organisms. note: therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. however, in emergency cases where the causative organism has not been identified, therapy with amoxycillin may be useful. clinical judgement will decide whether combination with another antibiotic would provide a sufficiently broad spectrum of activity pending sensitivity test results. skin and skin structure: staphylococcus, non-penicillinase producing; streptococcus; e. coli (see section 5.1 pharmacodynamic properties - microbiology). respiratory (acute and chronic): h. influenzae; streptococcus; strep. pneumoniae; staphylococcus, non-penicillinase producing; e. coli (see section 5.1 pharmacodynamic properties - microbiology). genitourinary tract (complicated and uncomplicated, acute and chronic): e.coli (see section 5.1 pharmacodynamic properties - microbiology), p. mirabilis and strep. faecalis. gonorrhoea: n.gonorrhoeae (non-penicillinase producing). prophylaxis of endocarditis: amoxycillin may be used for the prophylaxis of bacterial endocarditis in individuals at particular risk, such as those with a prosthetic heart valve or those who have previously had endocarditis.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - amoxicillin trihydrate, quantity: 116.96 mg/ml (equivalent: amoxicillin, qty 100 mg/ml) - oral liquid, powder for - excipient ingredients: crospovidone; xanthan gum; sodium benzoate; hydrophobic colloidal silica anhydrous; magnesium stearate; aspartame; carmellose sodium; flavour - it is indicated for the treatment of the following infections due to susceptible strains of sensitive organisms: note therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. however, in emergency cases where the causative organism has not been identified, therapy with amoxycillin may be useful. clinical judgement will decide whether combination with another antibiotic would provide a sufficiently broad spectrum of activity pending sensitivity test results. skin and skin structure: staphylococcus, non-penicillinase producing; streptococcus; e.coli (see microbiology). respiratory (acute and chronic): h.influenzae, streptococcus; s.pneumoniae; staphylococcus, non-penicillinase-producing; e.coli (see microbiology). genitourinary tract (complicated and uncomplicated, acute and chronic): e.coli (see microbiology), p.mirabilis and s.faecalis. gonorrhoea: n.gonorrhoeae (non-penicillinase producing). prophylaxis of endocarditis: amoxil may be used for the prophylaxis of bacterial endocarditis in individuals at particular risk, such as those with a prosthetic heart valve or those who have previously had endocarditis.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - amoxicillin trihydrate, quantity: 28.9 mg/ml (equivalent: amoxicillin, qty 25 mg/ml) - suspension, powder for - excipient ingredients: saccharin sodium; sorbitol; colloidal anhydrous silica; xanthan gum; sunset yellow fcf; sodium citrate dihydrate; flavour - indications: treatment of the following infections due to susceptible strains of sensitive organisms. note. therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. however, in emergency cases where the causative organism has not been identified, therapy with amoxycillin may be useful. clinical judgement will decide whether combination with another antibiotic would provide a sufficiently broad spectrum of activity pending sensitivity test results. skin and skin structure: staphylococcus, non-penicillinase producing; streptococcus; e. coli (see microbiology). respiratory (acute and chronic): h. influenzae; streptococcus; strep. pneumoniae; staphylococcus, nonpenicillinase producing; e. coli (see microbiology). genitourinary tract (complicated and uncomplicated, acute and chronic): e. coli (see microbiology), p. mirabilis and strep. faecalis. gonorrhoea: n.gonorrhoeae (nonpenicillinase producing). prophylaxis of endocarditis: amoxycillin may be used for the prophylaxis of bacterial endocarditis in individuals at particular risk, such as those with a prosthetic heart valve or those who have previously had endocarditis.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - amoxicillin trihydrate, quantity: 57.4 mg/ml (equivalent: amoxicillin, qty 50 mg/ml) - oral liquid, powder for - excipient ingredients: silicon dioxide; sodium citrate; purified talc; aspartame; sodium benzoate; citric acid; guar gum; flavour - treatment of the following infections due to susceptible strains of sensitive organisms: note: therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. amoxycillin alone or in combination with another antibiotic, may be used in an emergency where the causative organism has not been identified. respiratory tract infections (acute and chronic) including acute otitis media (aom): h. influenzae; streptococcus; s. pneumoniae; staphylococcus, nonpenicillinase producing; e. coli (see microbiology). urogenital infections (complicated and uncomplicated, acute and chronic): e. coli (see microbiology), p. mirabilis and strep. faecalis. gonorrhoea: n. gonorrhoeae (nonpenicillinase producing). skin and skin structure infections: staphlococcus, nonpenicillinase producing; streptococcus, e. coli (see microbiology). prophlaxis of endocarditis: amoxycillin may be used for the prophylaxis of bacterial endocarditis in individuals at particular risk, such as those with a prosthetic heart valve or those who have previously had endocarditis. infections caused by pathogens with established penicillin g susceptibility should preferentially be treated with penicillin g.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - amoxicillin trihydrate, quantity: 1005 mg (equivalent: amoxicillin, qty 875 mg); potassium clavulanate, quantity: 149 mg (equivalent: clavulanic acid, qty 125 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; magnesium stearate; purified talc; povidone; silicon dioxide; triethyl citrate; hypromellose; titanium dioxide; ethylcellulose; cetyl alcohol; sodium lauryl sulfate - short-term treatment of bacterial infection at the following sites when caused by amoxycillin/clavulanic acid sensitive, beta-lactamase producing organisms. skin and skin structure infections. urinary tract infections (uncomplicated and complicated). upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis. lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis. appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to curam tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed in the microbiological section, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to curam tablets should not require the addition of another antibiotic due to the amoxycillin content of curam tablets.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - amoxicillin trihydrate 30.13 mg/ml equivalent to amoxycillin 25 mg/ml (6mg overage) - powder for oral suspension - 125 mg/5ml - active: amoxicillin trihydrate 30.13 mg/ml equivalent to amoxycillin 25 mg/ml (6mg overage) excipient: aspartame colloidal silicon dioxide disodium edetate dihydrate propylene glycol alginate raspberry sodium benzoate sodium citrate dihydrate sorbitol

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - amoxicillin trihydrate 28.75 mg/ml equivalent to amoxycillin 25 mg/ml - powder for oral suspension - 125 mg/5ml - active: amoxicillin trihydrate 28.75 mg/ml equivalent to amoxycillin 25 mg/ml

Australia - English - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - amoxicillin trihydrate, quantity: 1006.25 mg; potassium clavulanate, quantity: 148.875 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; isopropyl alcohol; propylene glycol; dichloromethane; purified talc; ethylcellulose; hypromellose; magnesium stearate; titanium dioxide; hyprolose; industrial methylated spirit - apo-amoxy/clav 500/125 and apo-amoxy/clav 875/125 tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (uncomplicated and complicated),lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis,upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.,skin and skin structure infection,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxicillin and clavulanic acid tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate.,the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to amoxicillin and clavulanic acid tablets should not require the addition of another antibiotic due to the amoxicillin content of these products.

Australia - English - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - amoxicillin trihydrate, quantity: 575 mg; potassium clavulanate, quantity: 148.875 mg - tablet, film coated - excipient ingredients: propylene glycol; magnesium stearate; croscarmellose sodium; dichloromethane; purified talc; microcrystalline cellulose; ethylcellulose; hypromellose; isopropyl alcohol; titanium dioxide; hyprolose; industrial methylated spirit - amoxyclav generichealth 500/125 and amoxyclav generichealth 875/125 tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (uncomplicated and complicated),lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis,upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.,skin and skin structure infection,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxicillin and clavulanic acid tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate.,the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to amoxicillin and clavulanic acid tablets should not require the addition of another antibiotic due to the amoxicillin content of these products.